The historical rank and industry rank for Nectar Lifesciences's FCF Margin % or its related term are showing as below:
NSE:NECLIFE'
s FCF Margin % Range Over the Past 10 Years
Min: -126.37 Med: 7.02 Max: 11.6
Current: -126.37
During the past 13 years, the highest FCF Margin % of Nectar Lifesciences was 11.60%. The lowest was -126.37%. And the median was 7.02%.
NSE:NECLIFE's FCF Margin % is ranked worse than 92.92% of 960
companies
in the Drug Manufacturers industry
Industry Median: 2.48
vs NSE:NECLIFE: -126.37
Nectar Lifesciences FCF Margin % Related Terms
Nectar Lifesciences FCF Margin % Historical Data
* Premium members only.
The historical data trend for Nectar Lifesciences's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Nectar Lifesciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nectar Lifesciences FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nectar Lifesciences's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Nectar Lifesciences's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nectar Lifesciences (NSE:NECLIFE) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Nectar Lifesciences and its competitors. According to the industry distribution chart, Nectar Lifesciences ranks #892 out of 960 companies in the Drug Manufacturers industry, placing it in the top 92.9%.
Is Nectar Lifesciences' FCF Margin % too high?
Nectar Lifesciences' current FCF Margin % is 0.00%. Based on the distribution chart, Nectar Lifesciences ranks #892 out of 960 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Nectar Lifesciences has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nectar Lifesciences' FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Nectar Lifesciences ranks #892 out of 960 companies for FCF Margin %. This places Nectar Lifesciences in the lower half of its industry. The industry median FCF Margin % is 2.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.48, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Nectar Lifesciences and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nectar Lifesciences's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nectar Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Nectar Lifesciences (NSE:NECLIFE) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹6.86, compared to a current price of ₹11.58 — trading 68.8% above its estimated fair value. The current FCF Margin % is 0.00%. Nectar Lifesciences' overall GF Score™ is 43/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Nectar Lifesciences (NSE:NECLIFE), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nectar Lifesciences (NSE:NECLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, Nectar Lifesciences stock appears to be overvalued.
The current stock price of ₹11.58 is trading 68.8% above its estimated GF Value™ of ₹6.86.
GuruFocus considers Nectar Lifesciences to be Significantly Overvalued.
Key valuation signals for NSE:NECLIFE:
FCF Margin %: 0.00%
GF Value™: ₹6.86 vs. price of ₹11.58 (68.8% above fair value)
No single metric tells the full story. See the NSE:NECLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nectar Lifesciences Ltd is an India-based pharmaceutical company specializing in Cephalosporins. It is engaged in manufacturing specialized pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage formulations. It operates in the business segment of Pharmaceuticals Products. The Company is also in the Menthol business and succeeded in both domestic and international markets. Its business areas are APIs, Formulations, and Empty Hard Gelatin Capsules. Geographically, it derives a majority of its revenue from India.
43GF Score
Get the complete analysis for NSE:NECLIFE
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NECLIFE has been successfully added to your 
